课题基金 / 基金详情

Medicinal Chemistry and Lead Development Core - SR

Medicinal Chemistry and Lead Development Core - SR
药物化学和先导化合物开发核心 - SR
批准号:
10115591
负责人:
ASHISH KUMAR PATHAK
金额:
$224.04万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-07 至 2024-02-29

项目摘要

项目成果

ASHISH KUMAR PATHAK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Medicinal Chemistry and Lead Development Core (MCLDC) is a key component of the Antiviral Drug Discovery and Development Center (AD3C) that will contribute to the goals of the overall Center of Excellence for Translational Research (CETR) program to develop new replication inhibitors and other broad-based therapeutics for the treatment of emerging pathogens through its interaction with each of the individual projects and cores. The MCLDC will provide a) synthetic chemistry, b) structure-activity relationship (SAR) data and analysis, c) lead optimization chemistry, d) bioanalytical assays, e) structural biology and computational support, and d) compound storage and data management. In this role, the MCLDC, in conjunction with the Assay Core, will be the central focus of the translational research component of the program. As such, the MCLDC will work closely with the Assay Core and each of the Research Project teams. As new chemical entities are designed and synthesized during the lead generation and optimization processes, the Assay Core will test these analogs in SAR-driving assays. Testing of compounds for drug-like properties such as microsomal stability and solubility; and in vitro Absorption, Distribution, Metabolism and Excretion (ADME) will be an integral part of SAR studies from the early developmental phase. Appropriate lead compounds will be provided to the various Research Project teams for advanced studies including efficacy, mechanism of action, and other experiments. The resulting data on lead compounds from the Assay Core and Research Projects will then be analyzed by the MCLDC to drive the iterative lead optimization and in vivo PK studies to completion, resulting in optimized leads with drug-like properties for animal studies. The lead candidates will have met the go/no go decision criteria set for activity, potency and drug-like properties. The goal for the end result of this process will be identification of novel optimized lead molecules that are appropriate for IND applications. The MCLDC will incorporate key personnel of other Cores and Research Project teams into the prioritization and decision–making procedures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Medicinal Chemistry and Lead Development Core - SR
Medicinal Chemistry and Lead Development Core - SR
New Adjuvant Technologies for a Marburg Virus Vaccine
  • 批准号:
    7103977
  • 项目类别:
  • 资助金额:
    $25.03万
  • 财政年份:
    2004
  • 负责人:
    ASHISH KUMAR PATHAK
  • 依托单位:
New Adjuvant Technologies for a Marburg Virus Vaccine
  • 批准号:
    6890901
  • 项目类别:
  • 资助金额:
    $2.52万
  • 财政年份:
    2004
  • 负责人:
    ASHISH KUMAR PATHAK
  • 依托单位:
海外基金